In the letter, Kenneth Londoner, Chairman & CEO of
Topics discussed in the letter include:
- The latest PURE EP™ software features and functionality that, to our knowledge, no other intracardiac signaling technology provides.
- Data demonstrating BioSig’s capacity to drive clinical excellence.
- Research and development for an artificial intelligence (AI) medical device platform.
- Robust intellectual property and manufacturing upgrade.
- Fundraising and capital allocation.
- Vision for the future and commitment to shareholders.
To read the letter in its entirety, please visit ir.biosig.com/presentations.
About
The Company’s product, the PURE EP™ Platform, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed; (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the
Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 55Greens Farms Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
Source:
2023 GlobeNewswire, Inc., source